Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

167.67USD
4:00pm EDT
Change (% chg)

$1.11 (+0.67%)
Prev Close
$166.56
Open
$165.89
Day's High
$168.03
Day's Low
$165.81
Volume
922,414
Avg. Vol
1,065,493
52-wk High
$181.74
52-wk Low
$130.09

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $125,122.70
Shares Outstanding(Mil.): 751.22
Dividend: 1.00
Yield (%): 2.40

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 17.63 41.28 37.71
EPS (TTM): 9.45 -- --
ROI: 11.17 -9.20 14.43
ROE: 26.15 -9.24 15.61

BRIEF-Amgen declares quarterly dividend of $1 per share

* Board of directors declared a $1.00 per share dividend for q3 of 2016 Source text for Eikon: Further company coverage: )

Jul 22 2016

BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA

* Amgen and UCB submit biologics license application for romosozumab to the FDA

Jul 22 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug

Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

Jul 21 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug

July 21 Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

Jul 21 2016

BRIEF-Allergan, Amgen collaborating on development, commercialization of four oncology biosimilars

* In neoadjuvant phase of study, which included chemotherapy, there were more serious adverse events reported in ABP 980 group

Jul 21 2016

BRIEF-Amgen announces settlement of securities litigation

* Settlement class consists of purchasers of Amgen's publicly-traded securities during period from April 22, 2004, through May 10, 2007

Jul 20 2016

FDA panel backs Valeant psoriasis drug with risk program

Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

Jul 19 2016

UPDATE 2-U.S. FDA panel backs Valeant psoriasis drug with risk program

July 19 Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

Jul 19 2016

FDA knocks back Novartis copy of Amgen's drug Neulasta

U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.

Jul 19 2016

U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta

July 19 U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.

Jul 19 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.